To facilitate genotyping of Toxoplasma gondii in vitreous fluid of patients with severe or atypical ocular toxoplasmosis, polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) assays were developed for SAG3 (p43) and SAG4 (p18), 2 single-copy surface antigen genes. Together with strategies for SAG1, SAG2, and B1, multilocus RFLP analyses were performed on PCR-amplified parasite DNA present in 12 clinical specimens. Most samples (8/12) were not infected by type II or type III mouse-avirulent strains. Only 1 type III and 3 type II strains were identified, all from immunosuppressed patients. In 6 otherwise healthy adults and in 1 immunosuppressed patient, the SAG1 allele associated with mouse virulence was amplified. Of 12 samples, 3 possessed true type I strains; 5 of 12 had new recombinant genotypes with alleles typical of type I or III strains at all loci examined. The unusual bias toward type I and/or recombinant genotypes bearing the SAG1 type I allele associated with mouse virulence in immunocompetent adults has important implications for the epidemiology and efficacious treatment of ocular toxoplasmosis.
The protozoan parasite Toxoplasma gondii is widespread in nature with a high prevalence in many species of warm-blooded animals. Toxoplasmosis in humans is common and establishes itself as a lifelong chronic infection after consumption of undercooked meat harboring tissue cysts or from accidental ingestion of oocysts shed in cat feces. In immunocompetent adults, the disease is of variable severity, ranging from asymptomatic to influenza-like symptoms, lymphadenopathy, and ocular disease. When acquired congenitally or as a consequence of reactivation in immunocompromised patients, T. gondii can be fatal. Variation in the clinical presentation and severity of disease in susceptible persons has been attributed to several factors, including the genetic heterogeneity of the host and the genotype of the parasite responsible for infection [1] [2] [3] .
The population biology of T. gondii indicates that, despite the existence of a well-described sexual cycle in cats, the parasite appears to reproduce in nature largely clonally, with sexual recombination occurring only extremely rarely. Of the 106 iso-lates genotyped to date at multiple loci, most (93) fall into 1 of only 3 distinct lineages: types I (17), II (52), and III (24) [4] . These 3 clonal types most likely represent remarkably successful genotypes for the niches so far examined-primarily diseased humans, domestic animals, and livestock. Rarely, strains with novel genotypes are isolated. On the basis of very limited analyses, the genotypes of the latter strains are consistent with their being naturally occurring recombinants of the 3 archetypal lineages, which suggests occasional mating [5] . These apparent recombinants presumably are representative of the total genetic diversity to be found in nature when isolates from unusual hosts or perhaps those that are asymptomatic or cause clinically atypical disease are eventually sampled and carefully analyzed.
Toxoplasmosis is one of the most common causes of infectious retinitis in both immunocompetent and immunosuppressed persons, accounting for 30%-50% of all cases of posterior uveitis in the United States [6, 7] . Until recently, toxoplasma retinochoroiditis in adults was believed to result mainly from periodic reactivation of latent cysts associated with congenital infection. Although this does occur, studies in Southern Brazil, France, and the United States indicate that chronic, postnatally acquired ocular toxoplasmosis in otherwise healthy adults is quite prevalent [8] [9] [10] . An outbreak of acute toxoplasmosis associated with municipal drinking water in Victoria, Canada, illustrates this point: ∼20% of the 100 infected persons who experienced overt clinical symptoms went on to develop acute ocular disease as a result of the outbreak, which indicates a high rate of ocular involvement with acquired disease [11, 12] . Because the strains responsible for ocular toxoplasmosis have not been identified unequivocally, it has not been clear whether the genotype of T. gondii correlates with incidence, severity, or type of ocular disease. Type I strains, however, have been implicated in several outbreaks associated with a high frequency of ocular toxoplasmosis [8, 13, 14] .
Polymerase chain reaction (PCR) strategies for the detection of T. gondii DNA in intraocular fluid composed of vitreous and/or aqueous humor from patients with ocular disease have been applied only recently and have met with varying degrees of success [15] [16] [17] [18] . Accurate genotyping with these methods has not been feasible, primarily because of a lack of optimized PCR restriction fragment length polymorphism (RFLP)-based assays for ocular fluid. This study identified 2 new loci that, together with previously published methods, allowed us to analyze 5 independent loci to genotypically identify strains of T. gondii that cause ocular disease in both immunosuppressed and immunocompetent adults with a clinical diagnosis of severe or atypical ocular toxoplasmosis.
Materials and Methods
Clinical samples. We studied banked vitreous fluid specimens obtained from 18 patients (18 eyes) with atypical and/or severe ocular inflammation during the course of diagnostic or therapeutic procedures performed from December 1993 through August 2000. Each patient eventually was found to have ocular toxoplasmosis, on the basis of clinical findings, response to treatment, histopathologic study, and/or PCR detection. Banked vitreous fluid specimens from an additional 21 inflamed eyes without a diagnosis (diagnostic dilemmas) and from 92 eyes with vitreoretinal disease not caused by T. gondii (64 with uveitis and 28 without inflammation) served as controls.
PCR amplification. All specimens were stored at or below Ϫ20ЊC until the assays were performed. Two nested primer pairs were used in all PCRs. Specimens were thawed at room temperature and were boiled for 10 min, and a small aliquot was taken to assay for T. gondii DNA by PCR. Some of the vitreous fluid specimens were ethanol precipitated before receipt, as described elsewhere [18] .
For each gene, 2-5 mL of boiled vitreous or ethanol precipitate (depending on the total amount available) was subjected to PCR amplification by using external primers (ext), followed by nested amplification with the internal primers (int) with 1 mL of round 1 product as template. Both rounds used 5 mL of PCR buffer (10ϫ Perkin-Elmer PCR buffer containing 15 mM MgCl 2 ), 0.1 mM dNTP mix, 10 pmol of each primer, and 1.5 U of Taq DNA polymerase in a total reaction volume of 50 mL. Each of the 35 cycles consisted of 94ЊC for 30 s, 60ЊC for 30 s, and 72ЊC for 30 s. We used 2 dilutions of a commercial preparation of RH strain (type I) T. gondii DNA (Advanced Biotechnologies) as strong-and weakpositive controls. In addition, in the strain typing assays, an aliquot of each genomic DNA from a type I (RH), type II (Prugniaud), and type III (CEP) strain were analyzed. One water (DNA-free) negative control was tested with each assay. Samples were amplified in an automated thermocycler (Perkin-Elmer GeneAmp PCR System 9700). The amplification products were visualized on an ethidium-stained 8% polyacrylamide gel.
Genetic markers. To determine the genotype of the T. gondii strain in the vitreous fluid samples, we used PCR to amplify gene products from 5 independent (4 were single copy) loci, each with distinctive RFLP patterns, to assign the allele present and ultimately the genotype of the infecting strain. The 5 genetic markers used in this study were B1, SAG1, SAG2, SAG3, and SAG4. Primer sequences and diagnostic RFLPs for B1, SAG1, and SAG2 have been described elsewhere [4, [19] [20] [21] . In brief, the primers were as follows (all sequences in 5 -3 orientation): Burg B1, forward (F) ext , GGAAC-TGCATCCGTTCATGAG, F int , TGCATAGGTTGCAGTCACT-G, reverse (R) ext , TCTTTAAAGCGTTCGTGGTC, and R int , GGC-GACCAATCTGCGAATACACC; Grigg B1, F ext , TGTTCT-GTCCTATCGCAACG, F int , TCTTCCCAGACGTGGATTTC, R ext , ACGGATGCAGTTCCTTTCTG, and R int , CTCGACAATA-CGCTGCTTGA; SAG1, F ext , GTTCTAACCACGCACCCTGAG, F int , CAATGTGCACCTGTAGGAAGC, R ext , GTGGTTCTCCG-TCGGTGTGAG, and R int , TTATCTGGGCAGGTGACAAC; 5 -SAG2, F ext , GCTACCTCGAACAGGAACAC, F int , GAAATGTT-TCAGGTTGCTGC, R ext , GCATCAACAGTCTTCGTTGC, and R int , GCAAGAGCGAACTTGAACAC; 3 -SAG2, F ext , TCTGTTC-TCCGAAGTGACTCC, F int , ATTCTCATGCCTCCGCTTC, R ext , TCAAAGCGTGCATTATCGC, and R int , AACGTTTCACGAA-GGCACAC; SAG3, F ext , CAACTCTCACCATTCCACCC, F int , T-CTTGTCGGGTGTTCACTCA, R ext , GCGCGTTGTTAGACAA-GACA, and R int , CACAAGGAGACCGAGAAGGA; and SAG4, F ext , TACGATTTCAAGAAGGCGCT, F int , GGACGACGATGA-AACAAAGA, R ext , GTTCTTTCCCGTGTCCTTGA, and R int , C-AGAAGGGTATGGTTTCCTTCT. Primers for SAG3 and SAG4 were selected after DNA sequencing of 3 representative strains: type I (RH), type II (Prugniaud), and type III (CEP) revealed multiple polymorphic restriction endonuclease sites capable of identifying the allele present at these 2 loci. The SAG3 PCR product was digested with either NciI, Sau3AI, or AlwNI, to identify diagnostic restriction fragments (figure 1). Amplified SAG4 product was digested with SacI or Sau3AI (figure 2).
DNA sequencing. For sequencing, PCR products were gel purified from low-melt agarose gels, followed by recovery on glass beads, using the UltraClean 15 DNA purification kit (MoBio Labs). Sequencing was done at the Stanford Protein and Nucleic Acids facility on 0.5-1.0 mg of purified DNA by using 2 pmol of the forward or reverse internal primers.
Results

B1 gene assay.
Vitreous biopsy specimens submitted to our laboratory from 9 patients (9 eyes) clinically diagnosed as having atypical or severe ocular toxoplasmosis by the referring physician were first analyzed for the presence of T. gondii DNA by use of the nested PCR-based assay described by Burg et al. [19] for the detection of the B1 gene. The B1 gene is a 35-fold repetitive gene conserved in all T. gondii strains tested to date. Toxoplasma DNA was detected in 9 of 9 eyes, confirming the clinical diagnosis and providing a sensitivity of 100%. Controls used to check for contamination of reagents (2-5 mL of water diluted in PCR buffer and primers without vitreous material added) gave no detectable signal by this assay.
To test the specificity of the Burg B1 gene assay for detection of T. gondii DNA, we analyzed vitreous biopsies from 92 control specimens and 21 diagnostic dilemmas. Of the 92 control speci- mens, 0 of 64 from inflamed eyes and 2 of 28 from quiet eyes were positive for T. gondii DNA. Because no serologic information was available for the 2 B1-positive quiet eye controls, it could not establish whether these samples were false positives or indicated a latent but clinically asymptomatic T. gondii infection. Of the 21 specimens from diagnostic dilemmas, only 1 of 21 was positive for T. gondii, and the clinical picture for this patient is still evolving. These results indicate that the Burg B1 assay when done on vitreous biopsy specimens is both highly sensitive and reliable (у96% confidence) for the diagnosis of T. gondii infection in ocular disease, as reported elsewhere [16, 18] .
Strain typing. To identify the T. gondii genotype responsible for ocular infection in the B1-positive vitreous samples, multilocus RFLP analyses and, for some samples, DNA sequencing of PCR-amplified parasite DNA were done to determine the allele present at multiple single copy loci. Subsequent to our initial study, we received 9 additional vitreous fluid specimens (3 raw vitreous and 6 vitreous DNA precipitates) determined by the submitting laboratory (Jack Remington [JSR], Palo Alto Medical Foundation, Palo Alto, CA) to be positive for T. gondii DNA by use of the Burg B1 PCR assay. In total, 12 of the B1-positive clinical samples (our 9 and 3 from JSR) possessed sufficient parasite material to permit multilocus genotyping by the PCR-RFLP strategies described in the genetic markers section of Materials and Methods.
As shown in table 1, analysis by using previously described PCR-RFLP strategies for SAG1 identified 4 of the 12 samples as having the allele common to types II and III. Surprisingly, 7 of the 12 samples amplified the relatively rare type I allele (1 sample, JSR 14, did not amplify at SAG1). PCR-RFLP analysis at SAG2 tentatively discriminated between the 4 type II and III strains: 3 appeared to be type II and 1 appeared to be type III. For the 7 samples with a type I allele for SAG1, analysis at SAG2 showed that 4 (179, 2033, JSR 02, and JSR 05) were of an unusual genotype and apparently possessed the type III, rather than the type I, allele at this latter locus (table 1) . Thus, these results gave the first indication that strains 179, 2033, JSR 02, and JSR 05 possessed novel nonarchetypal genotypes.
The true extent of polymorphism between alleles cannot be fully assessed by RFLP analyses, so it was unclear whether the nonarchetypal strains found in samples 179, 2033, JSR 02, and JSR 05 in fact possessed a type I allele at SAG1 and a type III allele at SAG2 or if new alleles exist. Among archetypal strains, only 2 alleles have been described for the coding region of SAG1 [22] (authors' unpublished data) and DNA sequencing of PCRamplified SAG1 from the nonarchetypal strains described here revealed no new allelic polymorphisms over 347 bp of the open To address these alternative explanations, we needed to develop sensitive and highly specific PCR-RFLP strategies at additional polymorphic loci. This necessitated sequencing the alleles from previously established type I, II, and III lineage strains. For this study, we used the well described RH, Prugniaud, and CEP strains, respectively, as our reference types I, II, and III defining strains. Our efforts focused on 2 candidate genes, SAG3 (p43) [23] and SAG4 (p18) [24] , which are single copy genes encoding T. gondii surface antigens. Sequence data for the SAG3 gene in the 3 archetypal lineages identified 31 SNPs in the coding sequence that could be identified easily by RFLP (figure 1) or DNA sequence analysis (figure 3 and data not shown; GenBank accession numbers: RH-SAG3, AF340227; Prugniaud-SAG3, AF340228; and CEP-SAG3, AF340229). For SAG4, similar analyses revealed 15 SNPs in the 3 archetypal strains (data not shown; GenBank accession numbers: RH-SAG4, AF340224; Prugniaud-SAG4, AF340225; and CEP-SAG4, AF340226). Three of these SNPs gave convenient RFLPs (figure 2).
We selected nested primers to amplify short regions of DNA containing the most relevant polymorphisms, and product was readily amplified from control preparations containing as few as 5 parasites (data not shown). Nine unique nucleotide polymorphisms are bracketed by the SAG3 internal primers (2 unique to type I, 5 unique to type II, and 2 unique to type III strains), whereas 14 nucleotide polymorphisms are encompassed by the SAG4 internal primers (14 unique to type III strains; type I and II strains share the identical sequence). The SAG3 locus is of note, since a single PCR amplification followed by digestion with NciI discriminates between the 3 alleles (figure 1).
SAG3 and SAG4 PCR-RFLP analysis was done using the vitreous of the 12 clinical specimens (table 1) . Despite repeated efforts, no SAG3 or SAG4 PCR product was amplified from V92 vitreous, no SAG3 PCR product was amplified from JSR 14 vitreous precipitate, and we were unable to identify SAG4 PCR product in 2033 vitreous. We attribute these results to too little parasite DNA in the samples rather than to an absence of the SAG3 or SAG4 genes, because it was difficult to amplify product at other loci in these samples. RFLP analysis of the PCR products amplified from patients RVG 06, RVG 08, and JSR 14 confirmed that these specimens likely possessed true type I strains because type I patterns were seen at the 2 new loci. For samples 179, 2033, JSR 02, JSR 05, and 2035, however, the PCR-RFLP data for SAG3 and SAG4 strongly supported the notion that these patients were infected by novel recombinants with alleles typical of either type I or type III strains at all loci examined (table 1) .
The strain responsible for infection in specimen 2035 was of special interest. It was initially assigned to the type I lineage after RFLP analysis at SAG1 and SAG2; however, it appears to be yet another novel recombinant possessing a type III allele at SAG3 and type I alleles at the other 3 loci. The possibility that these results are due to the presence of у2 strains infecting a single patient seems to be remote, because only 1 unambiguous signal was seen for all 4 single copy genes studied and, in mock analyses that used limiting amounts of genomic DNA, we found that a mixture of type I and III strains readily revealed the presence of both alleles (i.e., no preferential PCR amplification of 1 particular allele when DNA is limited; data not shown).
DNA sequencing directly on the 225 nt SAG3 and 269 nt SAG4 PCR products amplified from the clinical samples was next done to determine whether the RFLP analyses correctly predicted the allele present. As for SAG1 and SAG2, all the clinical samples were identical in their sequence polymorphisms to the allele type determined by RFLP analyses for SAG3 (figure 3) and SAG4 (data not shown). Of note, the JSR 14 SAG4 allele possessed 2 unique nucleotide polymorphisms in addition to the 14 SNPs that define a type I or II allele at this locus. This strain could be a true type I strain that has undergone a small amount of drift; however, because no other type I strain among 8 examined showed such polymorphism (authors' unpublished data) and because we examined only 2 loci, it is entirely possible that this is a recombinant strain (in which greater polymorphism is more often seen) [14, 25] .
We recently developed a PCR-RFLP genotyping strategy at the 35-fold repetitive B1 locus [20] . For samples with sufficient remaining material for PCR amplification, we performed B1 PCR-RFLP analysis. All samples genotyped at B1 as predicted on the basis of RFLP and sequence data accumulated for the 4 single copy genes (table 1) . One control vitreous sample (JSR 03), determined by the submitting laboratory to be T. gondii DNA negative by Burg B1 PCR assay, on initial analysis was also negative by our B1 PCR-RFLP assay, but on receipt of more sample and retesting, it gave a positive result. The fact that JSR 03 was from a Toxoplasma-seronegative patient and that the sample was amplifiable only at the B1 gene is consistent with contamination, but the amplification product (type II or III) was not present in any of the other samples analyzed at that time, all the negative controls were clean, and patients with ocular toxoplasmosis having negative serum titers have been described elsewhere [26, 27] . Insufficient material remained for further testing, so the status of this sample remains unclear.
Discussion
We developed PCR-RFLP-based assays for allele typing of Toxoplasma strains at 2 new loci, SAG3 and SAG4. With these assays and by analysis of 3 other polymorphic loci, B1, SAG1, and SAG2, in 12 isolates from patients experiencing severe or atypical ocular toxoplasmosis, we found infection caused by type I in 3 isolates, type II in 3, and type III in 1, plus 5 novel recombinant types. These findings were markedly different from the expected frequencies, as discussed below. RFLP analysis at any 1 locus would have misidentified the 5 recombinant strains. Even analysis at 3 loci (e.g., SAG1, SAG2, and SAG4) would have mistakenly identified the 2035 isolate as type I, when it is another novel recombinant. Similarly, we cannot be sure that the 7 strains that genotype here as types I, II, or III are not novel recombinants until more polymorphic loci are identified and the samples are analyzed further. Unfortunately, the limited material available preclude such analyses on the samples studied here. Nevertheless, our results clearly reinforce the limitations of typing based on only 1 or 2 loci, especially with isolates sampled from exotic host species or geographically remote areas or from patients who have differing disease presentations.
Studies of mice have shown that infection with the 3 lineages of T. gondii results in dramatically different outcomes: Type I strains are highly virulent, whereas types II and III are relatively avirulent [13, 28] . As yet, there are few data for correlating the strain of infecting parasite with the outcome of human disease. In several studies, a substantial majority (∼60%-80%) of symptomatic infections in immunocompromised patients (e.g., those with AIDS or lymphoma or transplant recipients) were of type II parasites, but congenital infections were less uniform, although type II dominated [4, 21, 29, 30] . Precise clinical findings were not described, and no breakdown was given with regard to disease outcome versus parasite type responsible for infection.
Our study focused on patients who presented with severe or clinically atypical toxoplasmic retinochoroiditis. Although the data set was limited, we saw a strong bias toward virulent type I lineage or recombinant genotypes (8/12 isolates) rather than of the type II expected, on the basis of environmental distribution and of previous work with infected humans. Moreover, in all 6 adults who were not immunocompromised (except perhaps as a result of the treatment for the disease), the relatively rare type I allele at SAG1 associated with mouse virulence was amplified. The disproportionate number of recombinant genotypes identified (5/12) was striking, and 4 appeared to be a distinct and new clonal lineage, type IV. Previous studies identified only 3 of 106 strains as having recombinant genotypes that possess alleles typical of type I and type III strains [4] . Thus, type I or these recombinant strains may be more likely to result in severe ocular disease in humans. Whether the SAG1 gene or perhaps a nearby gene partially determines virulence could not be determined by our limited study, but others have noted that a region upstream of this gene appears to correlate with severe disease in mice [5] .
Support for a possible link between ocular disease and parasite genotype is further strengthened by differences in the prevalence of retinal involvement in different epidemics of acquired toxoplasmosis. In an outbreak in Atlanta in 1977, only 1 (3.6%) of 28 clinically symptomatic infected persons developed ocular lesions due to T. gondii infection [31] . However, in a 1995 outbreak in Victoria, Canada, 20 (20.6%) of 97 persons had ocular disease, a significantly greater proportion [12] . The strain responsible for the Atlanta outbreak has not been identified, but the 1 isolate recovered from a patient in the Victoria outbreak was identified as a type I strain [14] . Although this strain was not from a patient who developed ocular toxoplasmosis, the epidemiology of this well-defined outbreak suggests that it resulted from a single source and thus, in all probability, a single strain [32] . In Erechim, Brazil, where T. gondii seropositivity is endemic, ∼18% (184/1042) of the population have recurrent ocular toxoplasmosis [8] . Two strains have been isolated from this region (OH3 and S11), and both have been genotyped as mouse-virulent strains possessing the type I allele at SAG1 [13] .
Three reports document the isolation of live parasites from immunocompetent adults experiencing acquired ocular toxoplasmosis; 2 isolates passaged in mice were virulent [33] [34] [35] and therefore likely were type I or at least were not types II or III. These results all support the notion that different strains cause different disease outcomes in humans and that type I or type I-like recombinant strains are more likely to be associated with ocular disease in immunocompetent adults. This information could substantially alter patient treatment, with more aggressive monitoring and treatment of infections caused by more virulent strains. This is important because the prevailing consensus is that T. gondii infections in healthy adults are self-limiting and thus clinically benign.
Ultimately, to interpret the significance of finding 1 strain dominating in a given disease scenario, we will need strain typing for the vast majority of human infection where Toxoplasma causes little if any disease. As yet, there is no information on the strains that predominate in these infections and such information likely will await the development of noninvasive methods for strain typing (e.g., serology), as well as more studies on the sources of human infection. For example, the association of type II strains with symptomatic disease in immunocompromised patients simply may reflect the prevalence of type II infection in asymptomatic persons, which in turn may derive from the abundance of type II infection in livestock destined for human consumption [21] or the ability of type II strains to form high numbers of cysts [3] . Alternatively, but less likely, type I strains may be the dominant infection of humans, which suggests that type II parasites are unusual for their ability to cause disease in AIDS patients.
